Latest revenue
$17.3M
as of 2026-03-31
Latest net income
$-3.9M
as of 2026-03-31
Net margin
-22.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $102.9M
- Enterprise value
- $102.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $12.23
- 52-wk low
- $2.59
- Beta
- —
- Shares out
- 24.2M
5-year trend
What this company does
Item 1. Business. Overview We are a medical technology company primarily focused on the design, development and commercialization of a next-generation portfolio of innovative testing products under our AVISE® brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). We believe our strong focus and extensive background in the field of rheumatology, combined with our commitment to exceptional customer service and support, position us well to respond to the needs of rheumatologists, primary care physicians, other…
AI summary unavailable — showing raw filing excerpt
Generated from XGN's filing dated 2026-03-10
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below, together with all of the other information included in this Annual Report, including our financial statements and related notes and "Management’s Discussion and Analysis of Financial Condition and Results of Operations," before making an investment decision to purchase or sell shares of our common stock. If 30 any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and…
AI summary unavailable — showing raw filing excerpt
Generated from XGN's filing dated 2026-03-10
Profitability
Gross margin
58.3%
2.1%Operating margin
-21.1%
13.8%Net margin
-30.0%
10.3%Return on equity
-114.3%
27.8%Return on assets
-34.4%
1.7%Leverage
Debt / equity
2.33×
36.9%Long-term debt / equity
1.28×
38.6%Debt / assets
69.9%
11.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $17.3M | +11.7% | $-3.9M | -4.8% | -22.7% |
Q4 2025 2025-12-31 | $16.6M | +21.8% | $-4.7M | -25.3% | -28.3% |
Q3 2025 2025-09-30 | $17.2M | +37.9% | $-7.1M | -40.9% | -41.1% |
Q2 2025 2025-06-30 | $17.2M | +14.2% | $-4.4M | -48.4% | -25.6% |
Q1 2025 2025-03-31 | $15.5M | +7.5% | $-3.8M | -11.7% | -24.2% |
Q4 2024 2024-12-31 | $13.7M | — | $-3.8M | — | -27.5% |
Q3 2024 2024-09-30 | $12.5M | -6.8% | $-5.0M | +7.1% | -40.2% |
Q2 2024 2024-06-30 | $15.1M | +6.6% | $-3.0M | +40.8% | -19.7% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on XGN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$679.8K
Net activity
−$679.8K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns XGN
Institutional value
$8.3M
Total shares held
3.7M
Distinct holders
25
-55 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 678.7K | $2.0M | — | New |
| 2 | KENNEDY CAPITAL MANAGEMENT LLC | 493.7K | $1.5M | +13.6K (+2.8%) | Added |
| 3 | Mink Brook Asset Management LLC | 369.0K | $1.1M | +15.3K (+4.3%) | Added |
| 4 | SEI INVESTMENTS CO | 244.2K | $732.7K | +126.2K (+107.0%) | Added |
| 5 | JANE STREET GROUP, LLC | 236.7K | $710.2K | +42.7K (+22.0%) | Added |
| 6 | BlackRock, Inc. | 125.9K | $377.7K | -3.7K (-2.9%) | Trimmed |
| 7 | First Eagle Investment Management, LLC | 125.2K | $375.7K | — | New |
| 8 | VANGUARD FIDUCIARY TRUST CO | 97.3K | $291.9K | — | New |
| 9 | T3 Companies, LLC | 72.0K | $216.0K | +15.0K (+26.3%) | Added |
| 10 | PERKINS CAPITAL MANAGEMENT INC | 71.8K | $215.4K | +53.2K (+286.5%) | Added |
| 11 | DIMENSIONAL FUND ADVISORS LP | 62.6K | $187.6K | +36.2K (+137.4%) | Added |
| 12 | AXQ CAPITAL, LP | 34.6K | $103.8K | — | New |
| 13 | UBS Group AG | 27.9K | $83.7K | -85.1K (-75.3%) | Trimmed |
| 14 | R Squared Ltd | 27.1K | $81.3K | +8.9K (+49.0%) | Added |
| 15 | Bank of New York Mellon Corp | 20.9K | $62.8K | -14.4K (-40.8%) | Trimmed |
| 16 | SRS Capital Advisors, Inc. | 20.9K | $62.8K | — | New |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 19.8K | $59.5K | -113.4K (-85.1%) | Trimmed |
| 18 | Penbrook Management LLC | 13.3K | $40.0K | -100 (-0.7%) | Trimmed |
| 19 | Truvestments Capital LLC | 6.2K | $18.5K | +0 (+0.0%) | No change |
| 20 | Vanguard Global Advisers, LLC | 4.1K | $12.4K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once XGN's latest filing finishes processing.